Charbel Moussa, MD, PhD, is an investigator in translational research from bench to beside. His publications documented a critical role for parkin in the clearance of amyloid-beta, alpha-Synuclein, TDP-43 and tau via autophagy, and demonstrated that ubiquitination induces parkin activity via treatment with FDA-approved anti-cancer drugs. These drugs are now in clinical trials for Parkinson's disease, Lewy body dementia and Alzheimer's disease.